Wardex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 4.20 M
- Company Age 78 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.94 Cr
- Revenue Growth -3.55%
- Profit Growth -10.04%
- Ebitda 16.28%
- Net Worth 9.76%
- Total Assets 11.82%
About Wardex Pharmaceuticals
Wardex Pharmaceuticals Private Limited (WPPL) was founded in India on 18 December 1946 and has a glorious history of 78 years and one month. Its registered office is in Madras-29, Tamil Nadu, India.
The Corporate was formerly known as Ward Blenkinsop & Co. (India) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 4.20 M.
The company currently has active open charges totaling ₹1.94 Cr.
Venkatraman Subramaniam, Syed Rizvi, Vitalapuram Subramanian, and Three other members serve as directors at the Company.
Company Details
-
Location
Madras-29, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397TN1946PTC005759
-
Company No.
005759
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Dec 1946
-
Date of AGM
27 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Wardex Pharmaceuticals?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Alexandre Postel
![]() |
Managing Director | 24-May-2011 | Current |
Board Members (5)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Venkatraman Subramaniam
![]() |
Director | 27-Jan-2018 | Current |
Syed Rizvi
![]() |
Director | 26-Feb-2021 | Current |
Vitalapuram Subramanian
![]() |
Director | 01-Feb-1999 | Current |
Jagdish Mehta
![]() |
Director | 19-Mar-2014 | Current |
Pascal Postel
![]() |
Director | 31-Dec-2020 | Current |
Financial Performance of Wardex Pharmaceuticals.
Wardex Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.55% decrease. The company also saw a substantial fall in profitability, with a 10.04% decrease in profit. The company's net worth moved up by a moderate rise of 9.76%.
![Graph illustrating revenue growth over time](/Images/financial/revenue-growth.webp)
![Graph showing profit and loss trends over time](/Images/financial/profit-loss.webp)
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Wardex Pharmaceuticals?
In 2023, Wardex Pharmaceuticals had a public holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
![Shareholding Indicator graph](/Images/tcc-login/Shareholding-Indiacator-1200.webp)
Charges (Loans)
₹1.94 Cr
₹0
Charges Breakdown by Lending Institutions
- Bnp Paribas : 0.75 Cr
- Banque Nationale De Paris : 0.69 Cr
- Catholic Syrian Bank Ltd. : 0.30 Cr
- Banque Natinale De Paris : 0.20 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
26 Sep 2014 | Bnp Paribas | ₹7.50 M | Open |
20 Sep 1996 | Banque Nationale De Paris | ₹6.90 M | Open |
21 Dec 1982 | Catholic Syrian Bank Ltd. | ₹3.00 M | Open |
10 Nov 1978 | Banque Natinale De Paris | ₹2.00 M | Open |
How Many Employees Work at Wardex Pharmaceuticals?
Wardex Pharmaceuticals has a workforce of 109 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
![Graph showing employee growth trends](/Images/tcc-login/Employee-Graph.webp)
Deals i
![Graph showing company valuation over time](/Images/tcc-login/Valuation-Graph-small.webp)
Gain comprehensive insights into the Deals and Valuation data of Wardex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wardex Pharmaceuticals's trajectory.
Rating
![Graph displaying rating trends over time](/Images/tcc-login/Rating-Graph-small.webp)
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
![Alert Indicator](/Images/tcc-login/Alert-Indicator-small.webp)
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.